• Synapse Medicine raised $28m, led by leading European venture capital firm Korelya Capital and former investors (XAnge, MACSF and BNP Paribas Development). This is the third fundraising round in three years for the startup, reaching a total of $40 million.
• The company, which is already expanding across Europe, plans to accelerate the rollout of its medication reconciliation platform in the United States. Co-founder and CEO Dr. Clement Goehrs will move to New York to expand his business in the United States.
• The company will increase its workforce to 150 people, with hiring planned in Paris, Bordeaux, Berlin, London, New York and Tokyo.

BORDEAUX, France, March 1, 2022 /PRNewswire/ —

Strengthen care coordination and patient safety

Medication reconciliation, the process of compiling a complete and accurate list of medications the patient is taking (including name, dosage, frequency, and route), is critical to preventing medication errors and ensuring patient compliance with treatment. In the United States, hospital readmissions account for more than $41 billion in healthcare expenditures annually. According to the Agency for Healthcare Research and Quality (AHRQ), 66% of readmissions are linked to preventable adverse health events, such as medication non-adherence.

Synaptic medicine is one of the fastest growing health tech startups in Europe, with a strong track record in medication reconciliation. He recently announced several partnerships with leading hospitals, such as APHP-Paris (France), the largest hospital in Europe, ranked eleventh best hospital in the world, and the German hospital The charityranked sixth.

With the Synapse platform, healthcare professionals can rely on robust medication reconciliation technology to prevent medication errors and improve patient safety. This streamlines the medication reconciliation process, allowing clinicians to manage treatments more efficiently at every transition of care and improving coordination with stakeholders outside of the hospital.

“At Synapse Medicine, we have developed a medication reconciliation solution that simplifies the process and reduces prescription discrepancies at each transition. This new round of funding is an important step to further facilitate medication reconciliation and improve patient safety in the United States,” according to Dr. Clement Goehrs, CEO and co-founder of Synapse Medicine.

Acceleration of growth with key recruitments and the launch of the New York office

In hyper-growth for three years, Synapse Medicine aims to continue to recruit new talent in the United States and internationally to reach 150 employees by the end of the year. Synapse Medicine aims to expand its team in the United States to pharmacists, sales and marketing.

With this new round of funding, Synapse Medicine is expanding its operations in North America with a new office in New York. Operations will be led by Dr. Clement Goehrs, CEO and co-founder of Synapse Medicine.

“We were deeply impressed with the founders’ vision and early understanding of the power of drug data that could protect patients and support all stakeholders in healthcare industries across the globe. We look forward to supporting the Synapse Medicine team in the US and Asia.” said Fleur Pellerin, President and co-founder of Korelya Capital.

“We are once again supporting the deployment of Synapse Medicine, a start-up that we spotted very early on. At that time, we were already impressed by the founders, who represent a new generation of entrepreneurial doctors, and by the real impact of the product in terms of public health. The participation of Mutuelles Impact in this round table, led by XAnge, will allow us to develop links with insurance companies and to disseminate the technology to the general public..” explains Guillaume Meulle, managing partner of XAnge.

About Synapse Medicine:
Synapse Medicine’s mission is to provide everyone with access to the best medicines. The startup, which works closely with the largest French university hospitals, has developed a Medication Intelligence platform dedicated to the proper use of drugs. Leader in its category, the solution is 100% independent of the pharmaceutical industry and is now used by thousands of healthcare professionals.

Press contacts: Nadjib Bennai – Marketing Manager; +33 7 87 04 74 73; [email protected]

About Korelya Capital:
Founded and chaired by Fleur Pellerin, former French Minister of Digital Economy and Culture, Korelya Capital is a late-stage venture capital fund with €500 million under management and offices in Paris, London and Seoul. Since its launch in 2016, Korelya Capital has notably invested in several European technological champions who have reached unicorn status (Vestiaire Collective, Glovo, Bolt, Ledger, etc.). Korelya Capital supports growth companies in their development with the ambition of creating a strong European technology scene, in particular thanks to valuable support in Asia via its Seoul office and its vast network. www.korelyacapital.com

About XAnge:

XAnge is a European venture capital firm based in Paris and Munich. We invest in innovative early-stage European technology companies operating in the areas of digital consumption, enterprise and data, Fintech and Deeptech. Since its creation in 2003, XAnge has accompanied more than 200 fast-growing companies in their entrepreneurial journey. We work alongside visionary founders with strong values ​​and international ambitions such as Gleamer, Implicity, Treefrog, MDoloris… XAnge is the Venture branch of Siparex, an independent investment group with 2 billion euros under management

Logo – https://mma.prnewswire.com/media/1667017/Synapse_Medicine_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/synapse-medicine-raises-28m-to-scale-its-medication-reconciliation-platform-301491716.html

SOURCE Synapse Medicine